Krefeld, Germany

Bernd Kubiak

This inventor holds 2 USPTO granted patents. Top assignee: Stockhausen Gmbh & Co Kg. Active years: 2005-2006.


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2005-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Bernd Kubiak: Innovator in Amino Alkyl(meth)acrylates

Introduction

Bernd Kubiak is a notable inventor based in Krefeld, Germany. He has made significant contributions to the field of chemistry, particularly in the preparation of amino alkyl(meth)acrylates. With a total of 2 patents to his name, Kubiak continues to push the boundaries of innovation in his area of expertise.

Latest Patents

Kubiak's latest patents focus on a method for preparing amino alkyl(meth)acrylates. This process involves transesterification from C–C-alkyl (meth)acrylates and aminoalcohols. The transesterification is carried out in the presence of at least one distannoxane of a specific general formula. This innovative approach enhances the efficiency and effectiveness of producing these important chemical compounds.

Career Highlights

Throughout his career, Bernd Kubiak has been associated with Stockhausen GmbH & Co. KG, where he has applied his expertise in chemical processes. His work has contributed to advancements in the production of various chemical products, showcasing his commitment to innovation and excellence in his field.

Collaborations

Kubiak has collaborated with notable colleagues, including Erich Kuester and Oliver Hoppe. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the development of new technologies.

Conclusion

In summary, Bernd Kubiak is a distinguished inventor whose work in amino alkyl(meth)acrylates has made a significant impact in the field of chemistry. His innovative methods and collaborations continue to inspire advancements in chemical processes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…